Real world data on dual BLyS/APRIL inhibition with telitacicept for lupus nephritis
LN patients receiving additional telitacicept treatment demonstrated better disease remission, particularly in those with type V LN and proteinuria ≥3 g/day, with a favorable safety profile in real-world clinical practice.
Authors
- Ying Tan (ORCID: https://orcid.org/0000-0002-8139-5758)
- Jingjing Jin (ORCID: https://orcid.org/0000-0001-9683-4402)
- Meng Tan
- Minghui Zhao (ORCID: https://orcid.org/0000-0003-2732-5721)
Institutions
- Hebei Medical University (CN)
- Ministry of Education of the People's Republic of China (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking University (CN)
- Ministry of Education (RO)
- Fourth Hospital of Hebei Medical University (CN)
- Peking University First Hospital (CN)
Publication Details
- Journal
- Nephrology Dialysis Transplantation
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1093/ndt/gfaf049
- Citations
- 2
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 3.34